Drug Action
Granisetron is a specific 5HT3-receptor antagonist which blocks 5HT3 receptors in the gastro- intestinal tract and in the CNS.
Source page 476
Loading InternPractice…
Individual generic drug information
Extracted information for Granisetron only.
Granisetron is a specific 5HT3-receptor antagonist which blocks 5HT3 receptors in the gastro- intestinal tract and in the CNS.
Source page 476
Nausea and vomiting induced by cytotoxic chemotherapy for planned duration of 3–5 days where oral antiemetics cannot be used ▶BY TRANSDERMAL APPLICATION USING PATCHES ▶Adult: Apply 3.1 mg/24 hours, apply patch to clean, dry, non-irritated, non-hairy skin on upper arm (or abdomen if upper arm cannot be used) 24–48 hours before treatment, patch may be worn for up to 7 days; remove at least 24 hours after completing chemotherapy Prevention of postoperative nausea and vomiting ▶BY INTRAVENOUS INJECTION ▶Adult: 1 mg, to be administered before induction of anaesthesia, dose to be diluted to 5 mL and given over 30 seconds Treatment of postoperative nausea and vomiting ▶BY INTRAVENOUS INJECTION ▶Adult: 1 mg, dose to be diluted to 5 mL and given over 30 seconds; maximum 3 mg per day Management of nausea and vomiting induced by cytotoxic chemotherapy or radiotherapy ▶BY MOUTH ▶Adult: 1–2 mg, to be taken within 1 hour before start of treatment, then 2 mg daily in 1–2 divided doses for up to 1 week following treatment, when intravenous route also used, maximum combined total dose 9 mg in 24 hours ▶BY INTRAVENOUS INJECTION, OR BY INTRAVENOUS INFUSION ▶Adult: 10–40 micrograms/kg (max. per dose 3 mg), to be given 5 minutes before start of treatment, dose may be repeated if necessary, further maintenance doses must not be given less than 10 minutes apart, for intravenous injection, each 1 mg granisetron diluted to 5 mL and given over not less than 30 seconds, for intravenous infusion, to be given over 5 minutes; maximum 9 mg per day
Source page 476
Subacute intestinal obstruction. susceptibility to QT-interval prolongation (including electrolyte disturbances)
Source page 476
Extracted information for Granisetron only.
→Appendix 1: granisetron
Source page 476
GENERAL SIDE-EFFECTS ▶Common or very common Constipation. headache SPECIFIC SIDE-EFFECTS ▶Common or very common ▶With intravenous or oral use Diarrhoea. insomnia ▶Uncommon ▶With intravenous or oral use Extrapyramidal symptoms. QT interval prolongation. serotonin syndrome ▶With transdermal use Appetite decreased. arthralgia. dry mouth. flushing. generalised oedema. vertigo ▶Rare or very rare ▶With transdermal use Dystonia
Source page 476
Manufacturer advises avoid.
Source page 477
Avoid—no information available.
Source page 477
Manufacturer advises caution.
Source page 477
Extracted information for Granisetron only.
▶With intravenous use For intravenous infusion, give intermittently in Glucose 5% or Sodium Chloride 0.9%; dilute up to 3 mL in 20–50 mL infusion fluid; give over 5 minutes.
Source page 477
There can be variation in the licensing of different medicines containing the same drug. Solution for injection ▶Granisetron (Non-proprietary) Granisetron (as Granisetron hydrochloride) 1 mg per 1 ml Granisetron 3mg/3ml concentrate for solution for injection ampoules | 10 ampoule P £60.00 Granisetron 1mg/1ml concentrate for solution for injection ampoules | 5 ampoule P £10.00–£20.00 | 10 ampoule P £20.00 Tablet ▶Granisetron (Non-proprietary) Granisetron (as Granisetron hydrochloride) 1 mg Granisetron 1mg tablets | 10 tablet P £51.20 DT = £40.80 Granisetron (as Granisetron hydrochloride) 2 mg Granisetron 2mg tablets | 5 tablet P s DT = £52.39 ▶Kytril (Atnahs Pharma UK Ltd) Granisetron (as Granisetron hydrochloride) 1 mg Kytril 1mg tablets | 10 tablet P £52.39 DT = £40.80 Granisetron (as Granisetron hydrochloride) 2 mg Kytril 2mg tablets | 5 tablet P £52.39 DT = £52.39 Transdermal patch ▶Sancuso (Kyowa Kirin Ltd) Granisetron 3.1 mg per 24 hour Sancuso 3.1mg/24hours transdermal patches | 1 patch P £56.00 DT = £56.00
Source page 477
Extracted information for Granisetron only.
▶With transdermal use Patients should be advised not to expose the site of the patch to sunlight during use and for 10 days after removal.
Source page 477
Filter the extracted dose blocks for this individual drug.
First line only; read the complete Indications and dose section above.
Apply 3.1 mg/24 hours, apply patch to clean,
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 476
First line only; read the complete Indications and dose section above.
1 mg, to be administered before induction of
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 476
First line only; read the complete Indications and dose section above.
1 mg, dose to be diluted to 5 mL and given over
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 476
First line only; read the complete Indications and dose section above.
1–2 mg, to be taken within 1 hour before start of
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 476
First line only; read the complete Indications and dose section above.
10–40 micrograms/kg (max. per dose 3 mg), to
This is a first-line fragment. Read the full Indications and Dose section above.
Candidate age grouping · source page 476